<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534079</url>
  </required_header>
  <id_info>
    <org_study_id>pulmozyme-nasal-cf</org_study_id>
    <nct_id>NCT00534079</nct_id>
  </id_info>
  <brief_title>Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis</brief_title>
  <official_title>Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis - a Double Blind Placebo-controlled Cross-over, Bicenter, Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality
      of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a
      dysfunction of chloride channels in exocrine glands, leading to retention of secretions and
      consecutive chronic inflammation with bacterial superinfections.

      The prospective placebo controlled cross-over study aims at the evaluation of a nasally
      inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variations in the Sino-nasal-outcome test SNOT-20 adapt CF (primary nasal parameters: obstruction of nasal breathing, sneeze stimulus, permanent nose running, thick-mucous nasal discharge, earaches)</measure>
    <time_frame>day 1, 29, 57 and 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variations in the Sino-nasal-outcome test SNOT-20 adapt CF (secondary nasal parameters, general quality of live parameters and total SNOT 20 adapt. CF score)</measure>
    <time_frame>day 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of pathological alterations visible in MRT images of nose and paranasal sinuses (in selected patients)</measure>
    <time_frame>day 1, 29, 57, 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the nasal lavage fluid and in the serological markers of inflammation</measure>
    <time_frame>day 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rhinoscopic findings</measure>
    <time_frame>day 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rhinomanometric findings</measure>
    <time_frame>day 1, 29, 27 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rhinosinusitic and pulmonary exacerbations during therapy</measure>
    <time_frame>day 1 - 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for decongestants or nasal lavage during treatment</measure>
    <time_frame>day 1 - 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Dornase alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 days of sinonasal inhalation (Pari Sinus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>28 days of sinonasal inhalation (Pari Sinus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dornase alfa (Pulmozyme)</intervention_name>
    <description>1 x 2,5 ml per day, inhalation use, for 28 days</description>
    <arm_group_label>Dornase alfa</arm_group_label>
    <arm_group_label>isotonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotonic saline</intervention_name>
    <description>1 x 2,5 ml per day, inhalation use, for 28 days</description>
    <arm_group_label>Dornase alfa</arm_group_label>
    <arm_group_label>isotonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a confirmed diagnosis of cystic fibrosis based on: 3 positive sweat
             chloride tests and/or genetic characterisation

          -  Subject is 5 years of age or older

          -  Subject has chronic or recurrent rhinosinusitic disorders

          -  Subject is able to comply with the procedures scheduled in the protocol

          -  Women of childbearing potential are only included into the study, if they are using an
             effective method of birth control during the protocol (e.g. implants, combined oral
             contraceptives, injectables, some IUDs, sexual abstinence or vasectomised partner)

        Exclusion Criteria:

          -  Subject has a critical condition defined as: FEV1 &lt; 30% and / or SaO2 &lt; 93% without
             O2-substitution; need of O2-substitution

          -  Subject had an ENT surgery within 6 months prior to study

          -  Subject shows signs of nasal bleeding

          -  Subject has an ear drum perforation

          -  Subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with
             need of additional systemic antibiotic therapy

          -  Subject has a new therapy with nasal topic steroids during treatment interval

          -  Subject has a new systemic steroid therapy

          -  Subject is unlikely to comply with the procedures scheduled in the protocol

          -  Subject has a known allergic reaction to the medication

          -  Subject is pregnant or breastfeeding

          -  Patient participates in another clinical trial within 30 days prior to study entry or
             30 days after end of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Mainz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Jena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Würtemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mukoviszidosezentrum der Friedrich-Schiller-Universität</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mainz JG, Michl R, Arnold C. Response to Karadag. J Cyst Fibros. 2014 Sep;13(5):602-3. doi: 10.1016/j.jcf.2014.07.005. Epub 2014 Jul 28.</citation>
    <PMID>25081561</PMID>
  </reference>
  <results_reference>
    <citation>Mainz JG, Schien C, Schiller I, Schädlich K, Koitschev A, Koitschev C, Riethmüller J, Graepler-Mainka U, Wiedemann B, Beck JF. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst Fibros. 2014 Jul;13(4):461-70. doi: 10.1016/j.jcf.2014.02.005. Epub 2014 Mar 1.</citation>
    <PMID>24594542</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>PD Dr. Jochen G. Mainz</investigator_full_name>
    <investigator_title>Head of CF Center</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis and chronic rhinosinusitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

